Neurosense Therapeutics Ltd.'s market cap is currently ―. The company's EPS TTM is $-0.923; its P/E ratio is -1.84; Neurosense Therapeutics Ltd. is scheduled to report earnings on May 29, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	-
Gross Profit	-	-	-	-	-
EBIT	-	$ -2.98M	$ -3.45M	$ -2.69M	-
EBITDA	-	$ -2.98M	$ -3.45M	$ -2.69M	-
Net Income Common Stockholders	-	$ -2.99M	$ -3.48M	$ -2.71M	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 3.58M	$ 8.44M	$ 10.37M	$ 13.74M	$ 11.06M
Total Assets	$ 7.71M	$ 9.23M	$ 11.45M	$ 14.36M	$ 11.43M
Total Debt	$ 147.00K	$ 173.00K	$ 190.00K	$ 207.00K	$ 0.00
Net Debt	$ -3.44M	$ -8.27M	$ -10.18M	$ -13.53M	$ -11.06M
Total Liabilities	$ 2.09M	$ 1.38M	$ 1.62M	$ 2.25M	$ 2.42M
Stockholders Equity	$ 5.62M	$ 7.85M	$ 9.84M	$ 12.11M	$ 9.01M
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in USD

Neurosense Therapeutics Ltd. Earnings and Revenue History

Income Statement >

Neurosense Therapeutics Ltd. Debt to Assets

Balance Sheet >

Neurosense Therapeutics Ltd. Cash Flow

Cash Flow >

Neurosense Therapeutics Ltd. Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing